Search results for "Arrhythmia"

showing 10 items of 210 documents

Arrhythmia profile in acromegaly.

1992

In a controlled study, the cardiac involvement and arrhythmia profile of 32 patients with acromegaly were correlated with endocrine parameters (somatomedine C, growth hormone), clinical score and duration of the disease. Data were compared with those of 50 controls free of cardiac disease. Stress ECG, 24 h Holter monitoring and echocardiography were performed. Supraventricular premature complexes occurred no more often in acromegalics than in controls. Both prevalence and severity of ventricular arrhythmia, however, were significantly higher in patients compared to controls (P less than 0.01). 15/32 (48%) acromegalic patients had complex ventricular arrhythmias (Lown III-IV) as compared wit…

AdultMalemedicine.medical_specialtyAdenomaConcentric hypertrophyLeft ventricular hypertrophyElectrocardiographyInternal medicineAcromegalymedicineHumanscardiovascular diseasesAgedmedicine.diagnostic_testbusiness.industryArrhythmias CardiacHeartMiddle Agedmedicine.diseaseEndocrinologyEchocardiographyGrowth HormoneAmbulatoryAcromegalycardiovascular systemCardiologyExercise TestFemaleCardiology and Cardiovascular MedicinebusinessComplicationElectrocardiographyHormoneEuropean heart journal
researchProduct

Effect of intravenous flecainide on atrial vulnerability in man.

1985

Sixteen patients were investigated by means of programmed atrial stimulation at 2 different driving rates: 100/min and 120/min. All patients had an increased atrial vulnerability at both driving rates. After the administration of intravenous flecainide (1 mg/kg bodyweight as a bolus, followed by the same amount infused over a period of 20 minutes), the increased vulnerability was abolished in 11 and 9 patients, respectively. In the remaining patients the rate of induced atrial tachyarrhythmia decreased. These findings correlate with a significant prolongation of the effective refractory period of the right atrium and a corresponding significant shortening of its relative refractory period. …

AdultMalemedicine.medical_specialtyAdolescentRefractory Period ElectrophysiologicalRefractory periodElectrocardiographyBolus (medicine)PiperidinesInternal medicinemedicineHumansPharmacology (medical)Infusions ParenteralHeart AtriaFlecainideAgedFlecainidemedicine.diagnostic_testbusiness.industryAtrial vulnerabilityEffective refractory periodAtrial fibrillationArrhythmias CardiacMiddle Agedmedicine.diseaseAtrial FlutterAnesthesiaCardiologyFemalebusinessElectrocardiographyAnti-Arrhythmia AgentsAtrial fluttermedicine.drugDrugs
researchProduct

Effect of intravenous flecainide on atrial vulnerability in man.

1983

Sixteen patients were investigated by means of programmed atrial stimulation at two different driving rates: 100 and 120/min. All patients had an increased atrial vulnerability at both driving rates. After intravenous flecainide application (1 mg/kg body weight as a bolus followed by the same amount given by infusion over a period of 20 min) the increased vulnerability was abolished in 11 and 9 patients respectively. In the remaining patients the rate of induced atrial tachyarrhythmia decreased. These findings correlate with a significant prolongation of the effective refractory period of the right atrium and a significant shortening of the relative refractory period of the right atrium. It…

AdultMalemedicine.medical_specialtyAdolescentRefractory periodBody weightElectrocardiographyBolus (medicine)PiperidinesHeart Conduction SystemInternal medicineDrug DiscoveryAtrial FibrillationmedicineHumanscardiovascular diseasesFlecainideGenetics (clinical)AgedFlecainidebusiness.industryAtrial vulnerabilityEffective refractory periodCardiac Pacing ArtificialGeneral MedicineAtrial arrhythmiasMiddle Agedmedicine.anatomical_structureAtrial Fluttercardiovascular systemCardiologyMolecular MedicineRight atriumFemalebusinessAnti-Arrhythmia Agentsmedicine.drugKlinische Wochenschrift
researchProduct

Increased prevalence of cardiac arrhythmias and transient episodes of myocardial ischemia in hypertensives with left ventricular hypertrophy but with…

1997

To evaluate the behavior of cardiac arrhythmias (CA) and transient episodes of myocardial ischemia (TEMI), in relation to the circadian pattern of blood pressure in patients suffering from arterial hypertension, with or without echocardiographically ascertained left ventricular hypertrophy (LVH), we studied 128 patients, 87 men (M) and 41 women (F), aging from 21 to 76 years, subdivided into two groups: Group I, including 66 patients with LVH (45 M and 21 F; mean age of 53.7 ± 9.1 years; Group II, including 62 patients without LVH ( 42 M and 20 F; mean age of 49.7 ± 9.5 years). Office blood pressure (OBP) as well as nighttime ambulatory blood pressure (ABP) were higher in patients with LVH …

AdultMalemedicine.medical_specialtyAmbulatory blood pressureHeart diseasePremature atrial contractionMyocardial IschemiaBlood PressureCoronary DiseaseVentricular tachycardiaLeft ventricular hypertrophyElectrocardiographyHeart RateInternal medicineHeart rateInternal MedicinemedicineHumanscardiovascular diseasesAgedbusiness.industryArrhythmias CardiacBlood Pressure Monitoring AmbulatoryMiddle Agedmedicine.diseaseEchocardiography DopplerCircadian RhythmBlood pressureHypertensioncardiovascular systemCardiologyFemaleHypertrophy Left VentricularSupraventricular tachycardiabusinessAmerican journal of hypertension
researchProduct

Haemodynamic effects of a single intravenous dose of lorcainide in patients with heart disease

1980

The cardiovascular effects of a single i.v. dose (2 mg/kg over 5 min) of lorcainide were studied in 14 patients with heart disease. In the haemodynamic part of the study (6 patients), the aortic and pulmonary systolic, diastolic and mean pressures, left ventricular systolic and end-diastolic pressures, cardiac output and the rate of rise of left ventricular pressure were measured before and for 30 min after administration of the drug. Lorcainide produced a slight and short-lasting decrease in the aortic and pulmonary systolic pressures, and all other pressure values remained unchanged. The cardiac output and systemic vascular resistance were not altered by lorcainide. It consistently depres…

AdultMalemedicine.medical_specialtyCardiac outputTime FactorsHeart DiseasesHeart diseaseBenzeneacetamidesDiastoleHemodynamicsBlood PressureLorcainidePiperidinesInternal medicinemedicineHumansPharmacology (medical)Cardiac OutputAgedPharmacologyEjection fractionbusiness.industryHeartGeneral MedicineMiddle Agedmedicine.diseaseMyocardial Contractionmedicine.anatomical_structureAnesthesiaVascular resistanceVentricular pressureCardiologyFemaleVascular ResistancebusinessAnti-Arrhythmia Agentsmedicine.drugEuropean Journal of Clinical Pharmacology
researchProduct

Clinical characteristics and determinants of the phenotype in TMEM43 arrhythmogenic right ventricular cardiomyopathy type 5.

2020

Arrhythmogenic right ventricular cardiomyopathy type V (ARVC-5) is the most aggressive heterozygous form of ARVC. It is predominantly caused by a fully penetrant mutation (p.S358L) in the nondesmosomal gene TMEM43-endemic to Newfoundland, Canada. To date, all familial cases reported worldwide share a common ancestral haplotype. It is unknown whether the p.S358L mutation by itself causes ARVC-5 or whether the disease is influenced by genetic or environmental factors. The purpose of this study was to examine the phenotype, clinical course, and the impact of exercise on patients with p.S358L ARVC-5 without the Newfoundland genetic background. We studied 62 affected individuals and 73 noncarrie…

AdultMalemedicine.medical_specialtyDNA Mutational AnalysisMutation MissenseDisease030204 cardiovascular system & hematologyVentricular Function LeftRight ventricular cardiomyopathySudden cardiac deathElectrocardiography03 medical and health sciences0302 clinical medicinePhysiology (medical)Internal medicinemedicineGeneticsHumans030212 general & internal medicineExerciseArrhythmogenic Right Ventricular DysplasiaEjection fractionTMEM43business.industryIncidence (epidemiology)HaplotypeMembrane ProteinsStroke VolumeDNAmedicine.diseasePhenotypePedigree3. Good healthPhenotypeMutation (genetic algorithm)CardiologyFemaleCardiology and Cardiovascular MedicinebusinessArrhythmogenic right ventricular cardiomyopathyArrhythmia
researchProduct

PQ Interval in Patients With Fabry Disease

2010

Fabry disease (FD) is an X-chromosomal inherited lysosomal storage disease resulting in intracellular storage of globotriaosylceramide. Cardiac involvement is most frequently manifested as left ventricular hypertrophy. However, patients with FD may also have from various conduction abnormalities particularly affecting atrioventricular (AV) conduction. The present study was designed to analyze primarily AV conduction abnormalities on baseline electrocardiograms of patients with FD and to investigate the correlation with echocardiographic findings. Electrocardiograms at rest of 207 patients with FD were compared to echocardiograms. PQ-interval shortening and first-degree AV block could be fou…

AdultMalemedicine.medical_specialtyDiastoleLeft ventricular hypertrophyMuscle hypertrophyCohort StudiesElectrocardiographyYoung AdultInternal medicinePrevalencemedicineHumanscardiovascular diseasesPR intervalAtrioventricular Blockmedicine.diagnostic_testVascular diseasebusiness.industryArrhythmias CardiacMiddle Agedmedicine.diseaseFabry diseaseEchocardiography DopplerElectrocardiographic FindingCardiologyFabry DiseaseFemaleHypertrophy Left VentricularCardiology and Cardiovascular MedicinebusinessElectrocardiographyThe American Journal of Cardiology
researchProduct

Investigating cardiac and respiratory determinants of heart rate variability in an information-theoretic framework.

2014

This study was aimed at comparing two alternative information-theoretic approaches for the combined analysis of heart rate variability (HRV) and respiration variability (RV). The approaches decompose the predictive information about HRV in two terms, quantifying respectively the information stored into HRV and that transferred to HRV from RV. Storage and transfer were assessed by the popular self entropy (SE) and transfer entropy (TE) measures, as well as by the alternative conditional SE (cSE) and cross entropy (CE) measures. The comparison was performed at a theoretical level, computing the exact values of the four measures for simulated cardiorespiratory dynamics, and on real data, estim…

AdultMalemedicine.medical_specialtyEntropyHead-Down TiltElectrocardiographyRespiratory RateHeart RateInternal medicinemedicineEntropy (information theory)Heart rate variabilityHumansArrhythmia SinusRespiratory systemVagal tonePaced breathingMathematicsCardiorespiratory fitnessHealthy VolunteersCross entropySettore ING-INF/06 - Bioingegneria Elettronica E InformaticaCardiologyMedicineTransfer entropyFemaleAlgorithmsAnnual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference
researchProduct

Relation of endocrine and cardiac findings in acromegalics

1992

Cardiac involvement in 32 acromegalics was related to endocrine parameters, clinical score and duration of the disease as well as compared to that of 50 controls free of cardiac disease. Stress ECG, 24h Holter monitoring and echocardiography revealed that supraventricular premature complexes did not occur more often in acromegalics than in controls, both prevalence and severity of ventricular arrhythmia, however, were higher in patients compared to controls: 15/32 (48%) acromegalics had complex ventricular arrhythmia as compared with 6/50 (12%) normal subjects (p less than 0.01). Repetitive ventricular arrhythmia was manifest in 10/32 (31%) patients but only in 4/50 (8%) controls (p less th…

AdultMalemedicine.medical_specialtyHeart diseaseAdenomaEndocrinology Diabetes and MetabolismConcentric hypertrophyCardiomegalyLeft ventricular hypertrophySeverity of Illness IndexElectrocardiographyEndocrinologyInternal medicineAcromegalyPrevalenceHumansMedicinecardiovascular diseasesPathologicalAgedbusiness.industryArrhythmias CardiacMiddle Agedmedicine.diseaseCircadian RhythmEndocrinologyGrowth HormoneAcromegalycardiovascular systemCardiologyFemalebusinessComplicationHormoneJournal of Endocrinological Investigation
researchProduct

Effects of drug therapy on cardiac arrhythmias and ischemia in hypertensives with LVH.

2001

Left ventricular hypertrophy (LVH) in hypertensive subjects is associated with an increased prevalence of ventricular arrhythmias. To evaluate the effect of antihypertensive treatment on cardiac arrhythmias (CA) and transient episodes of myocardial ischemia (TEMI), we studied 46 hypertensive patients with LVH, divided into four groups randomly treated with enalapril, hydrochlorothiazide (HCTZ), atenolol, or verapamil (SR-V) for 6 months. Office blood pressure and office heart rate values were recorded, in basal conditions, after 1 and 6 months of treatment, and all patients underwent echocardiography, electrocardiographic Holter monitoring, and stress testing. All drugs significantly lowere…

AdultMalemedicine.medical_specialtyHeart diseaseMyocardial IschemiaBlood PressureLeft ventricular hypertrophyHydrochlorothiazideEnalaprilInternal medicineHeart rateInternal MedicinemedicineHumanscardiovascular diseasesEnalaprilAntihypertensive AgentsAgedmedicine.diagnostic_testbusiness.industryArrhythmias CardiacMiddle Agedmedicine.diseaseAtenololBlood pressureHydrochlorothiazideTreatment OutcomeAtenololVerapamilHypertensioncardiovascular systemCardiologyElectrocardiography AmbulatoryFemaleHypertrophy Left VentricularbusinessElectrocardiographyAnti-Arrhythmia Agentsmedicine.drugAmerican journal of hypertension
researchProduct